ES2800673T3 - Métodos y materiales para evaluar una deficiencia de recombinación homóloga - Google Patents

Métodos y materiales para evaluar una deficiencia de recombinación homóloga Download PDF

Info

Publication number
ES2800673T3
ES2800673T3 ES15757372T ES15757372T ES2800673T3 ES 2800673 T3 ES2800673 T3 ES 2800673T3 ES 15757372 T ES15757372 T ES 15757372T ES 15757372 T ES15757372 T ES 15757372T ES 2800673 T3 ES2800673 T3 ES 2800673T3
Authority
ES
Spain
Prior art keywords
regions
hrd
loh
region
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15757372T
Other languages
English (en)
Spanish (es)
Inventor
Victor Abkevich
Kirsten Timms
Alexander Gutin
Julia Reid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54035301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2800673(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Application granted granted Critical
Publication of ES2800673T3 publication Critical patent/ES2800673T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Catalysts (AREA)
  • Carbon And Carbon Compounds (AREA)
ES15757372T 2014-08-15 2015-08-17 Métodos y materiales para evaluar una deficiencia de recombinación homóloga Active ES2800673T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037764P 2014-08-15 2014-08-15
US201414507412A 2014-10-06 2014-10-06
PCT/US2015/045561 WO2016025958A1 (en) 2014-08-15 2015-08-17 Methods and materials for assessing homologous recombination deficiency

Publications (1)

Publication Number Publication Date
ES2800673T3 true ES2800673T3 (es) 2021-01-04

Family

ID=54035301

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15757372T Active ES2800673T3 (es) 2014-08-15 2015-08-17 Métodos y materiales para evaluar una deficiencia de recombinación homóloga
ES20162059T Active ES2946251T3 (es) 2014-08-15 2015-08-17 Métodos y materiales para evaluar la deficiencia de recombinación homóloga

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20162059T Active ES2946251T3 (es) 2014-08-15 2015-08-17 Métodos y materiales para evaluar la deficiencia de recombinación homóloga

Country Status (10)

Country Link
US (3) US10400287B2 (ja)
EP (3) EP4234711A3 (ja)
JP (3) JP6877334B2 (ja)
AU (2) AU2015301390B2 (ja)
CA (1) CA2958801A1 (ja)
DK (2) DK3686288T3 (ja)
ES (2) ES2800673T3 (ja)
NZ (2) NZ766822A (ja)
PT (1) PT3180447T (ja)
WO (1) WO2016025958A1 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11154538B2 (en) 2016-02-29 2021-10-26 Synta Pharmaceuticals Corporation Combination therapy for treatment of ovarian cancer
WO2017178509A1 (en) * 2016-04-12 2017-10-19 Xentech Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients
US12062416B2 (en) 2016-05-01 2024-08-13 Genome Research Limited Method of characterizing a DNA sample
WO2018162439A1 (en) * 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN108663519A (zh) * 2017-04-21 2018-10-16 江苏希摩生物科技有限公司 快速预测和提高BRCA1/2野生型卵巢癌细胞对Olaparib敏感性的方法
US20200239969A1 (en) * 2017-10-16 2020-07-30 The Board Of Regents Of The University Of Texas System Methods and compositions for use of trex2 as diagnostic and prognostic marker for cancer
EP3924502A4 (en) * 2019-02-12 2023-01-25 Tempus Labs, Inc. BUILT-IN MACHINE LEARNING STRUCTURE FOR ESTIMATING HOMOLOGOUS RECOMBINATION DEFICIENCY
WO2021011507A1 (en) * 2019-07-12 2021-01-21 Tempus Labs Adaptive order fulfillment and tracking methods and systems
WO2021070039A2 (en) * 2019-10-09 2021-04-15 Immunitybio, Inc. Detecting homologous recombination deficiencies (hrd) in clinical samples
EP4073805B1 (en) 2019-12-10 2024-07-17 Tempus AI, Inc. Systems and methods for predicting homologous recombination deficiency status of a specimen
EP4150113A1 (en) * 2020-05-14 2023-03-22 Guardant Health, Inc. Homologous recombination repair deficiency detection
EP3945525A1 (en) 2020-07-27 2022-02-02 Sophia Genetics S.A. Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data
CN112410423B (zh) * 2020-11-03 2021-08-13 南京世和基因生物技术股份有限公司 同源重组缺失的标志物、检测方法以及检测系统
CN112397145A (zh) * 2020-11-19 2021-02-23 河南省肿瘤医院 一种基于芯片检测的hrd评分计算方法
WO2022150063A1 (en) * 2021-01-10 2022-07-14 Act Genomics (Ip) Co., Ltd. Homologous recombination deficiency determining method and kit thereof
US20240026462A1 (en) * 2021-01-10 2024-01-25 Ying Ja CHEN Homologous recombination deficiency determining method and kit thereof
CN112820351A (zh) * 2021-03-01 2021-05-18 江苏医联生物科技有限公司 检测肿瘤患者的突变和hrd评分指导用药的方法
CN112980834B (zh) * 2021-04-22 2021-08-17 菁良基因科技(深圳)有限公司 一种同源重组修复缺陷参考品及其制备方法和试剂盒
CN114999568B (zh) * 2021-06-28 2023-04-18 北京橡鑫生物科技有限公司 一种端粒等位基因不平衡tai的计算方法
CN113658638B (zh) * 2021-08-20 2022-06-03 江苏先声医学诊断有限公司 一种基于ngs平台的同源重组缺陷的检测方法和质控体系
CN113462784B (zh) * 2021-08-31 2021-12-10 迈杰转化医学研究(苏州)有限公司 一种构建用于同源重组修复缺陷检测的靶标集合的方法
US20230212653A1 (en) * 2021-12-08 2023-07-06 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency in breast cancer subtypes
CN114242170B (zh) * 2021-12-21 2023-05-09 深圳吉因加医学检验实验室 一种同源重组修复缺陷的评估方法、装置和存储介质
CN114283889A (zh) * 2021-12-27 2022-04-05 深圳吉因加医学检验实验室 一种矫正同源重组修复缺陷评分的方法及装置
KR102523938B1 (ko) * 2022-02-04 2023-04-19 가톨릭대학교 산학협력단 상동 재조합 결핍증 예측 모델의 모델링 방법
WO2024083971A1 (en) 2022-10-19 2024-04-25 Vib Vzw Method of determining loss of heterozygosity status of a tumor

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GB1432562A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
ES444380A1 (es) 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
DE3630497A1 (de) 1986-09-08 1988-03-10 Behringwerke Ag Cis-platin-komplexe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
DK252688A (da) 1987-05-08 1988-11-09 Sankyo Co Antitumorplatinkomplekser, fremgangsmaade til fremstilling deraf, samt deres terapeutiske anvendelse
US4996337A (en) 1987-06-23 1991-02-26 American Cyanamid Company Synthesis of cisplatin analogs
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5434256A (en) 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US4946954A (en) 1989-01-17 1990-08-07 Georgetown University Platinum pharmaceutical agents
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
EP0612248B1 (en) 1991-11-15 2003-08-20 Smithkline Beecham Corporation Composition containing cisplatin and topotecan as antitumor agent.
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
AU751956B2 (en) 1997-03-20 2002-09-05 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
GB9806324D0 (en) 1998-03-24 1998-05-20 Pharmacia & Upjohn Spa Antitumour synergetic composition
GB9808145D0 (en) 1998-04-17 1998-06-17 Zeneca Ltd Assay
US20030049613A1 (en) 1998-08-17 2003-03-13 Manuel Perucho Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
US6534293B1 (en) 1999-01-06 2003-03-18 Cornell Research Foundation, Inc. Accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing
US6261775B1 (en) 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
US7858331B2 (en) 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
DE60142921D1 (de) 2000-12-01 2010-10-07 Eisai Inc Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
IL163600A0 (en) 2002-03-01 2005-12-18 Ravgen Inc Methods for detection of genetic disorders
AU2003291281A1 (en) 2002-11-01 2004-06-07 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
US20070004621A1 (en) 2003-02-12 2007-01-04 Viji Shridhar Bex4 nucleic acids, polypeptides, and method of using
US20040170983A1 (en) 2003-02-27 2004-09-02 Danenberg Kathleen D. Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus
WO2004083816A2 (en) 2003-03-14 2004-09-30 John Wayne Cancer Institute Loss of heterozygosity of the dna markers in the 12q22-23 region
WO2005002508A2 (en) 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
WO2005004805A2 (en) 2003-07-02 2005-01-20 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
AU2004264421B2 (en) 2003-08-13 2011-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20080108057A1 (en) 2004-06-22 2008-05-08 Griffith Jeffrey K Allelic imbalance in the diagnosis and prognosis of cancer
US7860840B2 (en) 2004-10-05 2010-12-28 Microsoft Corporation Maintaining correct transaction results when transaction management configurations change
CA2584989A1 (en) 2004-10-22 2006-05-04 Sydney David Finkelstein Molecular analysis of cellular fluid and liquid cytology specimens for clinical diagnosis, characterization, and integration with microscopic pathology evaluation
US20070070349A1 (en) 2005-09-23 2007-03-29 Helicos Biosciences Corporation Optical train and method for TIRF single molecule detection and analysis
US8105768B2 (en) 2005-03-09 2012-01-31 Abbott Laboratories Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
WO2006110855A2 (en) 2005-04-12 2006-10-19 454 Life Sciences Corporation Methods for determining sequence variants using ultra-deep sequencing
WO2006116341A1 (en) 2005-04-21 2006-11-02 Alza Corporation Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes
WO2006128195A2 (en) 2005-05-27 2006-11-30 Dana-Farber Cancer Institute Methods of diagnosing and treating cancer by detection of chromosomal abnormalities
MX2007015852A (es) 2005-06-30 2008-02-22 Bionumerik Pharmaceuticals Inc Analogos de platino con ligandos de monoazol.
JP5477888B2 (ja) 2005-09-21 2014-04-23 バイオアレイ ソリューションズ リミテッド 単鎖プライマ−プロモータ−セレクタ構造とｉｖｔを用いたメッセージ発生量及び対立遺伝子コピー数の決定
US20080262062A1 (en) 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2680549A1 (en) 2007-03-12 2008-09-18 Alan D. D'andrea Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
MX2010002556A (es) 2007-09-07 2010-08-02 Fluidigm Corp Metodos y sistemas para determinar la variacion del numero de copia.
CN103169973A (zh) 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
CN101888777A (zh) 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
US20090246789A1 (en) 2008-03-25 2009-10-01 University Of South Carolina Gene Mutation Profiling of CSMD1
US20100086922A1 (en) 2008-05-30 2010-04-08 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
MX2011004606A (es) 2008-10-31 2011-05-25 Abbott Lab Clasificacion genomica de cancer colorrectal con base en patrones de alteraciones de numero de copias de gene.
US8206910B2 (en) 2008-12-08 2012-06-26 The Cleveland Clinic Foundation Targets for use in diagnosis, prognosis and therapy of breast cancer
KR100925337B1 (ko) 2009-05-25 2009-11-09 주식회사 마크로젠 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측
US20120322677A1 (en) 2009-10-19 2012-12-20 Stichting Het Nederlands Kanker Instituut Predicting benefit of anti-cancer therapy via array comparative genomic hybridization
WO2011106541A2 (en) 2010-02-24 2011-09-01 Myriad Genetics, Inc. Diagnostic methods involving loss of heterozygosity
ES2609931T3 (es) 2010-06-18 2017-04-25 Myriad Genetics, Inc. Métodos y materiales para evaluar la pérdida de heterocigosidad
WO2012019000A2 (en) 2010-08-04 2012-02-09 On-Q-ity Biomarkers for the identification monitoring and treatment of ovarian cancer
CA2807823C (en) 2010-08-24 2023-02-07 The Brigham And Women's Hospital, Inc. Methods for predicting anti-cancer response
KR20140024270A (ko) 2010-12-30 2014-02-28 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
EP3693473A1 (en) 2011-06-17 2020-08-12 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
FI2794907T4 (fi) * 2011-12-21 2023-03-27 Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi
NZ628813A (en) 2012-02-23 2015-10-30 Univ Denmark Tech Dtu Methods for predicting anti-cancer response
CA3190075A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CA2908745C (en) * 2013-04-05 2023-03-14 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
US11149316B2 (en) 2013-12-09 2021-10-19 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
WO2015108986A1 (en) 2014-01-16 2015-07-23 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity

Also Published As

Publication number Publication date
JP7229297B2 (ja) 2023-02-27
EP4234711A3 (en) 2023-09-20
US20170283879A1 (en) 2017-10-05
NZ728326A (en) 2024-08-30
JP6877334B2 (ja) 2021-05-26
EP3686288A1 (en) 2020-07-29
EP3180447B1 (en) 2020-03-11
WO2016025958A1 (en) 2016-02-18
DK3686288T3 (da) 2023-05-22
AU2015301390B2 (en) 2021-08-26
DK3180447T3 (da) 2020-06-15
CA2958801A1 (en) 2016-02-18
JP2017533693A (ja) 2017-11-16
EP4234711A2 (en) 2023-08-30
AU2021273600A1 (en) 2021-12-16
US20230117133A1 (en) 2023-04-20
AU2015301390A1 (en) 2017-02-02
JP2021112205A (ja) 2021-08-05
PT3180447T (pt) 2020-06-18
JP2023015394A (ja) 2023-01-31
EP3180447A1 (en) 2017-06-21
NZ766822A (en) 2024-08-30
EP3686288B1 (en) 2023-03-08
ES2946251T3 (es) 2023-07-14
US20190185939A1 (en) 2019-06-20
US10400287B2 (en) 2019-09-03

Similar Documents

Publication Publication Date Title
ES2800673T3 (es) Métodos y materiales para evaluar una deficiencia de recombinación homóloga
ES2777228T3 (es) Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer
ES2862331T3 (es) Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer
JP6700333B2 (ja) ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
CN118369439A (zh) 用于评估乳腺癌亚型中同源重组缺陷的方法和材料